Abstract:This study highlights aspects of the latest clinical research conducted on the relationship between immune checkpoints and tumor metastasis. The overview of each immune checkpoint is divided into the following three sections: 1) structure and expression; 2) immune mechanism related to tumor metastasis; and 3) clinical research related to tumor metastasis. This review expands on the immunological mechanisms of 17 immune checkpoints, including TIM-3, CD47, and OX-40L, that mediate tumor metastasis; evidence shows that most of these immune checkpoints are expressed on the surface of T cells, which mainly exert immunomodulatory effects. Additionally, we have summarized the roles of these immune checkpoints in the diagnosis and treatment of metastatic tumors, as these checkpoints are considered common predictors of metastasis in various cancers such as prostate cancer, non-Hodgkin lymphoma, and melanoma. Moreover, certain immune checkpoints can be used in synergy with PD-1 and CTLA-4, along with the implementation of combination therapies such as LIGHT-VTR and anti-PD-1 antibodies. Presently, most monoclonal antibodies generated against immune checkpoints are under investigation as part of ongoing preclinical or clinical trials conducted to evaluate their efficacy and safety to establish a better combination treatment strategy; however, no significant progress has been made regarding monoclonal antibody targeting of CD28, VISTA, or VTCN1. The application of immune checkpoint inhibitors in early stage tumors to prevent tumor metastasis warrants further evidence; the immune-related adverse events should be considered before combination therapy. This review aims to elucidate the mechanisms of immune checkpoint and the clinical progress on their use in metastatic tumors reported over the last 5 years, which may provide insights into the development of novel therapeutic strategies that will assist with the utilization of various immune checkpoint inhibitors.

Research Progress of Immune Checkpoints Blockade in the Tumor Immunotherapy

[Tracking Research Progress in the Modulatory Role of Gut Microbiome in Immune Checkpoint Inhibitors Applied in Cancer Treatment].

Research Progress of the Application of Immune Checkpoints in Tumor Radiotherapy

Tumor Immune Checkpoints and Their Associated Inhibitors

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases

The Breakthroughs in Cancer Immune Checkpoint Based Therapy: A Review of Development in Immune Checkpoint Study and its Application

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance

Predictive Biomarkers for Tumor Immune Checkpoint Blockade

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

Advances of Immune Checkpoints in Colorectal Cancer Treatment.

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints

Immune Checkpoint Inhibitors: Basics and Challenges

Advances in Research of Immune Checkpoints for Colorectal Cancer

Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis

The Application of Nanotechnology in Immune Checkpoint Blockade for Cancer Treatment

Progress of Drug Resistance Mechanism in Checkpoint Inhibitors

Lessons Learned from the Blockade of Immune Checkpoints in Cancer Immunotherapy